TY - JOUR
T1 - Active, specific immunotherapy for lung cancer
T2 - Hurdles and strategies using genetic modification
AU - Korst, Robert J.
AU - Crystal, Ronald G.
PY - 2003/10/1
Y1 - 2003/10/1
N2 - Active immunotherapy for lung cancer has been a challenge because of the poor antigenic characterization of these tumors and their ability to escape the immune response. However, knowledge of the mechanisms of anti-tumor immunity has expanded significantly over the past decade, leading to the development of more novel, specific strategies for augmenting the immune response. Genetic manipulation of tumor cells, immune cells, or both, may help overcome some of the previously encountered difficulties of immunotherapy. Laboratory and clinical investigations are currently ongoing to evaluate the feasibility and potential benefit of these novel approaches.
AB - Active immunotherapy for lung cancer has been a challenge because of the poor antigenic characterization of these tumors and their ability to escape the immune response. However, knowledge of the mechanisms of anti-tumor immunity has expanded significantly over the past decade, leading to the development of more novel, specific strategies for augmenting the immune response. Genetic manipulation of tumor cells, immune cells, or both, may help overcome some of the previously encountered difficulties of immunotherapy. Laboratory and clinical investigations are currently ongoing to evaluate the feasibility and potential benefit of these novel approaches.
UR - http://www.scopus.com/inward/record.url?scp=0141673669&partnerID=8YFLogxK
U2 - 10.1016/S0003-4975(03)00651-9
DO - 10.1016/S0003-4975(03)00651-9
M3 - Article
C2 - 14530047
AN - SCOPUS:0141673669
SN - 0003-4975
VL - 76
SP - 1319
EP - 1326
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -